Roger C. Causon

Zimmer Biomet (Netherlands)

Papers

2

Total Citations

70

H-Index

2

About

Roger C. Causon has made significant contributions to the field of bioanalytical chemistry, with a primary focus on developing rapid and robust methods for quantifying anti-cancer drugs in biological matrices. His work centers on the application of automated solid-phase extraction coupled with liquid chromatography–tandem mass spectrometry (LC-MS/MS) to enhance the speed, sensitivity, and reliability of therapeutic drug monitoring. Causon’s most cited research includes the development of a method for the rapid determination of chlorambucil (Leukeran™) and its active phenyl acetic acid mustard metabolite in human serum and plasma, a paper that has garnered 49 citations. He also established a similar approach for melphalan (Alkeran™), cited 21 times. These contributions are critical for pharmacokinetic studies and personalized medicine in oncology, enabling clinicians to optimize dosing and minimize toxicity. Causon’s work exemplifies the integration of automation and advanced mass spectrometry to address real-world clinical challenges, and his methods remain foundational for researchers and laboratories focused on cancer therapeutics.

Research Focus

Key Achievements

2
H-Index
2
Papers
70
Total Citations
35
Avg Citations/Paper
🏆 Most Cited Paper
Rapid determination of the anti-cancer drug chlorambucil (Leukeran™) and its phenyl acetic acid mustard metabolite in human serum and plasma by automated solid-phase extraction and liquid chromatography–tandem mass spectrometry
49 citations · 1999
📈 Most Prolific Year: 1999 (1 Papers)
🤝 Key Collaborators: 2
🏛 Institutions: Zimmer Biomet (Netherlands)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 1 days ago